Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Ulcerative Colitis]
Not Applicable
Completed
- Conditions
- lcerative colitis
- Registration Number
- JPRN-jRCT1080224534
- Lead Sponsor
- Takeda Pharmaceutical Company Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 1096
Inclusion Criteria
1. Have moderate or severe active UC
2. Have inadequate response to existing therapies
Exclusion Criteria
1.Patients with any contraindication for vedolizumab
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method